Zacks reiterates recommendation of anti-aging drugmaker Telomir despite 47% YTD loss – Oninvest Zacks says take a look at the stock ahead of human trials of Telomir's primary drug early next year

🧬Zacks Sees 7x Upside in #Telomir, Citing “Unlimited Market Potential”

Zacks SCR reiterated its Buy on #TELO, a small biotech targeting aging and neurodegenerative diseases, with a $15.50 PT.

What’s in Telomir’s pipeline that makes Zacks so confident? Find out here: en.oninvest.com/article/zack...

Biotech catalyst calendars and drug pipelines • BioPharmCatalyst Profit on the stock market by investing in biotech stocks

Biotech firm #Telomir has announced its pre-clinical results which confirm the efficacy of longevity compound Telomir-1, effectively reversing the aging process. No human trials yet but an impressive first step.

www.biopharmcatalyst.com/company/TELO...

Biotech catalyst calendars and drug pipelines • BioPharmCatalyst Profit on the stock market by investing in biotech stocks

#Telomir $TELO announced #preclinical results confirming the efficacy of Telomir-1, a compound designed to reverse the biological clock and effectively support #longevity.

#biotech

www.biopharmcatalyst.com/company/TELO...